# NEUROGT, INC.: Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | NEUROGT, INC. |
| Location | Chapel Hill, NC |
| Project | Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I |
| Project number | 5R44NS143501-02 |
| Mechanism | R44 |
| Institute | National Institute of Neurological Disorders and Stroke |
| Award | $1,484,525 |
| Awarded | 2026-09-14 |
| Project period | 2025-09-16 to 2027-08-31 |
| UEI | NQHRNCAD21P3 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11417197). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.